Monday, July 31, 2023 9:07:29 AM
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-a Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
https://www.benzinga.com/pressreleases/23/07/b33469123/mymd-pharmaceuticals-reports-statistically-significant-positive-topline-phase-2-results-for-next-g
Hi Ray Blanco - expecting to hear from you!
[trading halted until 9:50 am]
Recent MYMD News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:30:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:01:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:30:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 04:00:19 PM
- MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • Business Wire • 03/05/2024 02:15:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:13:35 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 04:27:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:57:03 PM
- MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing • Business Wire • 02/13/2024 04:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 02:15:12 PM
- MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis • Business Wire • 12/06/2023 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/19/2023 01:00:10 PM
- MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain • Business Wire • 10/19/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 09:00:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 08:30:23 PM
- MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023 • Business Wire • 10/04/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/08/2023 09:24:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/24/2023 09:58:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/18/2023 08:21:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:00:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 12:30:38 PM
- FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA) • Business Wire • 08/14/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 08:30:47 PM
- MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results • Business Wire • 08/02/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 08:30:32 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM